Pure Global: Brazil's New SaMD Rules - Unseen Compliance Traps for Innovators.

Impossibile aggiungere al carrello

Puoi avere soltanto 50 titoli nel carrello per il checkout.

Riprova più tardi

Rimozione dalla Lista desideri non riuscita.

Riprova più tardi

Non è stato possibile aggiungere il titolo alla Libreria

Per favore riprova

Non è stato possibile seguire il Podcast

Per favore riprova

Esecuzione del comando Non seguire più non riuscita

Pure Global: Brazil's New SaMD Rules - Unseen Compliance Traps for Innovators.

Ascolta gratuitamente

Vedi i dettagli del titolo

3 mesi a soli 0,99 €/mese

Dopo 3 mesi, 9,99 €/mese. Si applicano termini e condizioni.

A proposito di questo titolo

Brazil is tightening its grip on the rapidly growing Software as a Medical Device (SaMD) market. A recent clarification from its regulatory agency, ANVISA, has introduced new, more stringent requirements for clinical evidence and cybersecurity, creating unexpected hurdles for global MedTech innovators. This move, aimed at increasing patient safety, could stall market entry plans for companies unprepared for this new level of scrutiny. This episode of LATAM MedTech Insights dives deep into what this new guidance practically means for manufacturers. We break down the specific documentation changes, analyze the strategic implications for companies targeting Brazil, and discuss the broader trend of increasing regulatory sophistication across Latin America. Case Study Spotlight: Imagine your cutting-edge diagnostic AI, already cleared in the US, is ready to launch in Brazil. Suddenly, ANVISA releases this new guidance demanding extensive local clinical data and cybersecurity protocols you don't have. Your launch is now stalled, and your investors are asking questions. This episode tackles that exact scenario. Key Takeaways in this Episode: * What are the three new documentation requirements for SaMD in Brazil that most companies will miss? * How does ANVISA's new cybersecurity expectation differ from the FDA's framework? * Is your existing clinical data from Europe or the US sufficient for a Brazilian submission now? * What specific local factors must be addressed in your risk management file for Brazil? * Could this new guidance actually create an advantage for companies that are prepared? * How will this impact the timeline and cost for registering a new SaMD product? At Pure Global, we specialize in demystifying complex regulatory landscapes. We offer end-to-end solutions for MedTech and IVD companies, leveraging local expertise and advanced data tools to streamline market access in over 30 countries, including Brazil. Don't let regulatory surprises derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can help.

Ancora nessuna recensione